ArticleJournal of diabetes investigation2026
Circulating miR-342-3p as a biomarker for diagnosing gestational diabetes mellitus and predicting adverse perinatal outcomes: A retrospective cohort study.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimsThis study evaluated the clinical utility of circulating miR-342-3p for diagnosing gestational diabetes mellitus (GDM) and predicting adverse perinatal outcomes (APOs).
methodsA retrospective cohort of 261 GDM women (the GDM group) and 261 propensity score-matched healthy controls (the Normal group) was analyzed. Circulating miR-342-3p levels were quantified by RT-qPCR, and diagnostic and predictive performances were assessed using receiver operating characteristic curves. Correlations with fasting plasma glucose (FPG), 2-h postprandial glucose (2hPG), and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were evaluated by Spearman's analysis. Logistic regression was used to analyze the independent association between circulating miR-342-3p expression and APOs.
resultsCirculating miR-342-3p was significantly elevated in GDM patients versus controls and demonstrated early diagnostic potential for GDM (AUC = 0.835). In GDM patients, miR-342-3p levels showed moderate positive correlations with FPG, 2hPG, and HOMA-IR (r = 0.780, 0.578, 0.613). miR-342-3p levels were elevated in both the GDM-APOs and the Normal-APOs groups compared with their respective non-APO subgroups. Circulating miR-342-3p yielded AUCs of 0.697 and 0.599 for predicting APOs in the GDM and Normal groups, respectively. After adjusting for pre-pregnancy BMI, parity, FPG, and 2hPG, the ORs for APOs per unit increase in miR-342-3p were 1.338 in the GDM group and 2.284 in the Normal group.
conclusionCirculating miR-342-3p may serve as a valuable adjunctive biomarker for early GDM screening. Across both GDM and non-GDM populations, circulating miR-342-3p is significantly associated with APOs, suggesting cross-population applicability, though GDM status may modulate the strength of this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.